The prevalence of primary and secondary helicobacter pylori resistance to clarithromycin and probable contributing cofactors: Data from Southeastern Anatolia

Hepato-Gastroenterology

Volumn 55, Issue 81, 2008, Pages 289-293

  Tüzün, Yekta ^a   Bayan, Kadim ^a   Yilmaz, Serif ^a,b   Dursun, Mehmet ^a   Ozekinci, Tuncer ^a  

^a DICLE UNIVERSITY   (Turkey)

^b DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Clarithromycin; Helicobacter pylori; Resistance

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; PANTOPRAZOLE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DYSPEPSIA; EPSILOMETER TEST; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SEX RATIO; STOMACH BIOPSY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; TURKEY;

EID: 41549165626     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Dunn BE, Cohen H, Blaser MJ: Helicobacter pylori. Clin Microbiol Rev 1997; 10:720-741.
2. World Health Organization: IARC monographs on the evaluation of carcinogenic risks to human, vol. 61. Geneva: World Health Organization 1994:177-240.
3. Vakil N: Helicobacter pylori treatment: a practical approach. Am J Gastroenterol 2006; 101(3):497-499.
4. Vakil N: Primary and secondary treatment for Helicobacter pylori in the United States. Rev Gastroenterol Disord 2005; 5(2):67-72.
5. Bazzoli F, Olivieri L, De Luca L, Pozzato P, Lehours P, Megraud F: Therapy and drug resistance in Helicobacter pylori infection. Dig Liver Dis 2000; 32(Suppl 3):S207-210.
6. Xia H H-X, Talley NJ: Prospects for improved therapy for Helicobacter pylori infection. Exp Opin Invest Drugs 1996; 5:959-976.
7. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY: Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001; 161(9):1217-1220.
8. Liu W, Lu B, Xiao S, Xu W, Shi L, Zhang D: Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection. Chin J Intern Med 1996; 35:803-806.
9. Laine L, Suchower L, Frantz J, Connors A, Neil G: Low rate of emergence of clarithromycin resistant Helicobacter pylori with amoxycillin co therapy. Aliment Pharmacol Ther 1998; 12:887-892.
10. Loo VG, Fallone CA, De Souza E, Lavallee J, Barkun AN: In vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. J Antimicrob Chemother 1997; 40:881-883.
11. Glupczynski Y: Antimicrobial resistance in Helicobacter pylori: a global overview. Acta Gastroenterol Belg 1998; 61:357-366.
12. Lind T, Megraud F, Unge P, Bayerdorffer E, O'morain C, Spiller R, et al: The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-253.
13. Sevin E, Lamarque D, Berrhouma A, Delchier JC, Soussy CJ, Tankovic J: Prevalence of resistance of Helicobacter pylori to clarithromycin and metronidazole following treatment failure and genetic basis of resistance to clarithromycin. Gut 1997; 41(Suppl 1):A10. (Abstract)
14. Ozcay F, Kocak N, Temizel IN, Demir H, Ozen H, Yuce A, et al: Helicobacter pylori infection in Turkish children: comparison of diagnostic tests, evaluation of eradication rate, and changes in symptoms after eradication. Helicobacter 2004; 9(3):242-248.
15. Simsek H, Balaban YH, Gunes DD, Hascelik G, Ozarlan E, Tatar G: Alarming clarithromycin resistance of Helicobacter pylori in Turkish population. Helicobacter. 2005; 10(4):360-361.
16. Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161-1181.
17. Broutet N, Guillon F, Sauty E, Lethuaire D, Megraud F: Survey of the in vitro susceptibility of Helicobacter pylori to antibiotics in France-Preliminary results. Gut 1998; 43(Suppl 2):A11. (Abstract)
18. Rozynek E, Dziersanowska D, Celinska-Cedro D, Jeljaszewicz J: Primary resistance to metronidazole and other antibiotics of Helicobacter pylori isolated from children in Poland. Eur J Clin Microbiol Infect Dis 1997; 16:943-944.
19. Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, et al: Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000; 44:2214-2216.
20. Glupczynski Y, Megraud F, Lopez-Brea M: European multicentre survey of in vitro antimicrobial resistance in HP. Eur J Clin Microbiol Infect Dis 2001; 20:820-823.
21. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN: A systematic review of helicobacter eradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13:1047-1055.
22. Street ME, Cauana P, Caffarelli C, Magliani W, Manfredi M, Fornaroli F, et al: Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection. Advantages and outcome. Arch Dis Child 2001; 84:419-422.
23. Us D, Hascelik G: Seroprevalence of Helicobacter pylori infection in an asymptomatic Turkish population. J Infect 1998; 37:148-150.
24. Yilmaz E, DoGan Y, Gurgoze MK, Unal S: Seroprevalence of Helicobacter pylori infection among children and their parents in eastern Turkey. J Pediatr Child Health 2002; 38:183-186.
25. Tompkins DS, Perkin J, Smith C: Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 1997; 2:185-187.
26. Alarcon T, Domingo D, Lopez-Brea M: Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents 1999; 12:19-26.
27. Xia HX, Fan XG, Talley NJ: Clarithromycin resistance in Helicobacter pylori and its clinical relevance. World J Gastroenterol 1999; 5:263-266.
28. Uygun A, Kadayifci A, Kilinc R, Dagalp K: Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. Am J Gastroenterol 1999; 94:3073-3074.
29. Pamuk ON, Pamuk GE, Celik A, Uzunismail H: Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? Am J Gastroenterol 2000; 95:1839-1840.
30. Kantarçeken B, Yildirim B, Karincaoǧlu M, Aladaǧ M, Hilmioglu F: Helicobacter pylori and antibiotic resistance. Turk J Gastroenterol 2000; 11(2):141-145.
31. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, et al: Factors influencing the eradication of H. pylori with triple therapy. Gastroenterology 1992; 102:493-496.
32. Cutler AF, Schubert TT: Patient factors affecting H. pylori eradication with triple therapy. Am J Gastroenterol 1993; 88:505-509.
33. Perri F, Clemente R, Festa V, et al: Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol 1998; 30:146-150.
34. Katicic M, Prskalo M, Ticak M: Is PPP-triple therapy of greater efficacy in peptic ulcer than in non-ulcer dyspeptic patients? Gut 2000; 47(Suppl 1):A104. (Abstract)
35. Labenz J, Leverkus F, Borsch G: Omeprazole plus amoxicillin for cure of Helicobacter pylori infection: factors influencing the treatment success. Scand J Gastroenterol 1994; 29:1070-1075.
36. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129:1027-1030.
37. Tankovic J, Lamarque D, Lascols C, Soussy CJ, Delchier JC: Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Aliment Pharmacol Ther 2001; 15(5):707-713.
38. Abdul Aal GM, Dajani AI, Nounou M, Awad S, Abdul Rasheed Z, Gautam S, et al: Resolution of gastritis induced by Helicobacter pylori 4±5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin. Digestion 1999; 60:286-297.
39. Moshkowitz M, Konikoff FM, Peled Y, Santo M, Hallak A, Bujanover Y, et al: High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 1995; 36:845-847.
40. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A: Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001; 15:1023-1029.
41. Georgopoulos SD, Ladas SD, Karatapanis S, Mentis A, Spiliadi C, Artikis V, et al: Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxycillin, and clarithromycin. Dig Dis Sci 2000; 45:63-67.
42. Miyaji H, Azuma T, Ito S, Suto H, Yamazaki Y: Susceptibility of helicobacter pylori isolates to metronidazole, claritromycin, amoxycillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther 1997; 11:1131-1136.
43. Wurzer H, Rodrigo L, Stander D, Archambault A, Rokkas T, Skandalis N, et al: Short course therapy with amoxycillin clarithromycin triple for 10 dayseadicates Hp and heals duodenal ulcer. Aliment Pharmacol Ther 1998; 11:943-952.
44. Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, et al: The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 2002; 8:388-383.
45. Burette A, Lamy V, Ramdani B, Cappelli J, DePrez C, Glupczynski Y: Lansoprazole (30mgOD vs BID) with amoxicillin and clarithromycin to cure Helicobacter pylori infection. Gut 1996; 39(Suppl 2):A33.
46. Cayla R, Zerbib F, Talbi P, Megraud F, Lamouliatte H: Pre and post treatment clarithromycin resistance of Helicobacter pylori strains: a key factor of treatment failure. Gut 1995; 37(Suppl 1):A55.
47. Schütze K, Hentschel E, Hirschl AM: Clarithromycin or amoxicillin plus high dose ranitidine in the treatment of Helicobacter pylori positive functional dyspepsia. Eur J Gastroenterol Hepatol 1996; 8:41-46.
48. Maeda S, Yoshida H, Ogura K, Kanra F, Shiratori Y, Omata M: Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. Gut 1998; 43:317-321.
49. Suzuki J, Mine T, Kobayasi I, Fujita T: Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. Helicobacter 1998; 3:59-63.